An in silico study: Novel targets for potential drug and vaccine design against drug resistant H. pylori

Chiranjeevi Pasala; Chandra Sekhar Reddy Chilamakuri; Sudheer Kumar Katari; Ravina Madhulitha Nalamolu; Aparna R Bitla; Amineni Umamaheswari

doi:10.1016/j.micpath.2018.05.037

An in silico study: Novel targets for potential drug and vaccine design against drug resistant H. pylori

Microb Pathog. 2018 Sep:122:156-161. doi: 10.1016/j.micpath.2018.05.037. Epub 2018 May 23.

Authors

Chiranjeevi Pasala¹, Chandra Sekhar Reddy Chilamakuri², Sudheer Kumar Katari¹, Ravina Madhulitha Nalamolu¹, Aparna R Bitla³, Amineni Umamaheswari⁴

Affiliations

¹ Bioinformatics Centre, Department of Bioinformatics, SVIMS University, Tirupati, 517507, India.
² Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, CB2 0RE, UK.
³ Department of Biochemistry, SVIMS University, Tirupati, 517507, AP, India.
⁴ Bioinformatics Centre, Department of Bioinformatics, SVIMS University, Tirupati, 517507, India. Electronic address: svims.btisnet@nic.in.

PMID: 29800696
DOI: 10.1016/j.micpath.2018.05.037

Abstract

Gastric cancer risk and adverse ramifications by augmented multi-drug resistance (MDR) of Helicobacter pylori are alarming serious health concern. Combating through available drugs is a difficult task due to lack of appropriate common targets against genetically diverse strains. To improve efficacy, the effective targets should be identified and critically assessed. In the present study, we aim to predict the potential novel targets against H. pylori strains by employing computer aided approach. The genomic dataset of 53 H. pylori strains was comparatively processed and eventually predicted 826 'conserved gene products'. Further, we performed subtractive genomic approach in search of promising crucial targets through the combination of in silico analyses. Codon adaptation index (CAI) value calculation and literature surveys were also done in order to find highly expressed gene products with novelty. Consequently, four enzymes and three membrane proteins were prioritized as new therapeutic and vaccine targets respectively which found to have more interactors in network with high-confidence score, druggability, antigenicity and molecular weight <110 kDa. Therefore, our results underpin the importance of new targets may counteract with false-positive/negatives and facilitate appropriate potential targets for a new insight of reliable therapeutic development.

Keywords: Common proteins; Druggability; H. pylori; Metabolic pathways; Network analysis; Therapeutic targets.

MeSH terms

Anti-Bacterial Agents / isolation & purification*
Anti-Bacterial Agents / pharmacology
Bacterial Vaccines / immunology
Bacterial Vaccines / isolation & purification*
Computational Biology / methods*
Drug Design
Drug Discovery / methods*
Genetic Association Studies / methods
Helicobacter pylori / genetics*

Substances

Anti-Bacterial Agents
Bacterial Vaccines